ArticleThe New England journal of medicine2025
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in
Abstract readCase Reports
In one paragraph
Article in The New England journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Engineering "off-the-shelf" TCR-T cells: A transient mRNA platform for balanced alloreactivity and functionality.Molecular therapy. Oncology · 2026Article
- Bispecific antibodies are becoming the preferred standard of care in relapsed/refractory multiple myeloma.Blood advances · 2026Article
- Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.Nature medicine · 2026Article
- CAR-engineered neutrophils derived from induced pluripotent stem cells: a new frontier in cellular immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Review Article: Immune Effector Cell-Mediated Enterocolitis Following CAR-T Cell Therapy-Clinical Features, Pathophysiology and Management.Alimentary pharmacology & therapeutics · 2026Review
- CAR-T therapy for immune-mediated necrotizing myopathy: a review of mechanisms and emerging clinical evidence.Clinical rheumatology · 2026Review
- Article
- [The risk and management strategies for second primary tumor after CAR-T cell therapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Review
- T cell lymphomas: cancers of aberrant immune synapse signalling.Nature reviews. Immunology · 2026Review
- Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignancies.Blood neoplasia · 2026Article
- Targeting BCMA in patients with relapsed/refractory multiple myeloma in 1 to 3 prior lines of therapy.Blood advances · 2026Review
- Navigating clinical decision-making for IEC-enterocolitis.Blood advances · 2026Article
- Diagnosis and management of immune effector cell-associated enterocolitis after ciltacabtagene autoleucel.Blood advances · 2026Article
- Secondary peripheral T-cell lymphoma in a patient with DLBCL harboringJournal for immunotherapy of cancer · 2026Article
- Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen-Directed CAR T-Cell Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders.Nature reviews. Clinical oncology · 2026Review
- CAR T cells take on precancers.Nature medicine · 2026Article
- Non-viral targeted integration at the CISH locus enables CAR-NK cell engineering with enhanced anti-tumor activity.Molecular therapy. Oncology · 2026Article
- Distinct roles of STAT3 and STAT5 in CAR T cell therapy.Molecular therapy. Oncology · 2026Article
- Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Karlo PericaCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Nayan JainCenter for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York.
Michael ScordoCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Ruchi PatelMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York.
Ozgur Can ErenHematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York.ORCID 0000-0001-9889-2702
Utsav PatelDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York.
Gunes GundemComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York.
Dylan DomenicoComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York.
Sneha MitraComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York.
Nicholas D SocciMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York.
John K EverettDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Aoife M RocheDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Angelina PetrichenkoDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.ORCID 0000-0003-0600-0709
Gunjan L ShahCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Maria E ArcilaDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York.
Laetitia BorsuDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York.
Jae H ParkCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.ORCID 0000-0002-2903-5130
Steven M HorwitzCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Sergio A GiraltCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Ahmet DoganHematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York.
Christina LeslieComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York.
Elli PapaemmanuilComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York.
Frederic D BushmanDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.ORCID 0000-0003-4740-4056
Saad Z UsmaniCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Michel SadelainCenter for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York.
Sham MailankodyCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MLinking insertional mutagenesis and cell function to improve CAR T cell therapyR01CA241762 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BUSHMAN, FREDERIC D, MELENHORST, JAN J · 2019 to 2023
$3.1MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA241762
Abstract
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case of a T-cell lymphoma harboring a lentiviral integration in a known tumor suppressor,
Indexed as
B-Cell Maturation AntigenImmunotherapy, AdoptiveLymphoma, T-CellMultiple MyelomaTumor Suppressor Protein p53AgedCD4-Positive T-LymphocytesCell Transformation, NeoplasticFatal OutcomeFemaleHumansLentivirusReceptors, Chimeric AntigenB-Cell Maturation AntigenReceptors, Chimeric AntigenTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.